[Prognostic value of HbA1c and plasma glucose on one-year mortality in non-diabetic patients after myocardial infarction].
Impact pronostique de l’HbA1c et de la glycémie plasmatique (Gp) à la phase aiguë d’un infarctus du myocarde sur la mortalité à un an chez des patients non diabétiques.
Age Factors
Aged
Aged, 80 and over
Biomarkers
/ blood
Blood Glucose
/ analysis
C-Reactive Protein
/ analysis
Cause of Death
Female
Glycated Hemoglobin
/ analysis
Heart Disease Risk Factors
Humans
Logistic Models
Male
Middle Aged
Myocardial Infarction
/ blood
Non-ST Elevated Myocardial Infarction
/ blood
Prognosis
ROC Curve
ST Elevation Myocardial Infarction
/ blood
Stroke Volume
/ physiology
Time Factors
Troponin I
/ blood
Glycemic stress
HbA1c
Infarctus du myocarde
Mortalité à un an
Myocardial infraction
Non diabétique
Non-diabetic
One-year mortality
Stress glycémique
Journal
Annales de cardiologie et d'angeiologie
ISSN: 1768-3181
Titre abrégé: Ann Cardiol Angeiol (Paris)
Pays: France
ID NLM: 0142167
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
02
2020
accepted:
30
03
2020
pubmed:
29
8
2020
medline:
14
8
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
The usefulness of the combined assessment of HbA1c and plasma glucose (PG) in acute myocardial infarction (AMI) in non-diabetic patients remains unclear. In a large observational study, we aimed to identify the prognostic values of these biomarkers regarding one-year all-cause mortality in non-diabetic patients after AMI. From the "obseRvatoire des Infarctus de Côte d'Or" (RICO) survey database, we included all consecutive non-diabetic patients with AMI (n=6617) from May 2001 to December 2016. Exclusion criteria were: admission known or unknown diabetes, in-hospital death. The primary endpoint was all-cause one-year mortality. The secondary endpoints were: MACE, infarct size, LVEF<40% and GRACE risk score. Cut-off levels (high/low) were determined by ROC curve analysis for the prediction of one-year death (HbA1c 5.9% and PG 131mg/dL) to set up 4 groups: low HbA1c/low glucose (n=3158), low HbA1c/high glucose (n=1264), high HbA1c/low glucose (n=1378) and high HbA1c/high glucose (n=817). Elevation of PG was associated with elevated rate of LVEF<40%, STEMI, anterior wall location, DFG<60mL/min/m Admission PG and HbA1c had strong independent predictive value regarding one-year all-cause mortality in our non-diabetic patients with AMI. These biomarkers could be useful to identify the most-at-risk patients after AMI in order to reduce residual risk in this target population.
Sections du résumé
BACKGROUND
BACKGROUND
The usefulness of the combined assessment of HbA1c and plasma glucose (PG) in acute myocardial infarction (AMI) in non-diabetic patients remains unclear.
PURPOSE
OBJECTIVE
In a large observational study, we aimed to identify the prognostic values of these biomarkers regarding one-year all-cause mortality in non-diabetic patients after AMI.
METHODS
METHODS
From the "obseRvatoire des Infarctus de Côte d'Or" (RICO) survey database, we included all consecutive non-diabetic patients with AMI (n=6617) from May 2001 to December 2016. Exclusion criteria were: admission known or unknown diabetes, in-hospital death. The primary endpoint was all-cause one-year mortality. The secondary endpoints were: MACE, infarct size, LVEF<40% and GRACE risk score. Cut-off levels (high/low) were determined by ROC curve analysis for the prediction of one-year death (HbA1c 5.9% and PG 131mg/dL) to set up 4 groups: low HbA1c/low glucose (n=3158), low HbA1c/high glucose (n=1264), high HbA1c/low glucose (n=1378) and high HbA1c/high glucose (n=817).
RESULTS
RESULTS
Elevation of PG was associated with elevated rate of LVEF<40%, STEMI, anterior wall location, DFG<60mL/min/m
CONCLUSIONS
CONCLUSIONS
Admission PG and HbA1c had strong independent predictive value regarding one-year all-cause mortality in our non-diabetic patients with AMI. These biomarkers could be useful to identify the most-at-risk patients after AMI in order to reduce residual risk in this target population.
Identifiants
pubmed: 32854906
pii: S0003-3928(20)30055-X
doi: 10.1016/j.ancard.2020.03.020
pii:
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Troponin I
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
fre
Sous-ensembles de citation
IM
Pagination
180-191Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.